Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis-Reference-Cited by-同舟云学术

Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis

Published:2022-12-20 Issue:4 Volume:118 Page:744-747
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Hirano Ikuo¹^ORCID,Rothenberg Marc E.²³,Zhang Sandra⁴,de Oliveira Claudia⁴,Charriez Christina M.⁴,Coyne Karin S.⁵,Bacci Elizabeth Dansie⁶,Dellon Evan S.⁷

Affiliation:

1. Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA;

2. Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA;

3. University of Cincinnati College of Medicine, Cincinnati, Ohio, USA;

4. Bristol Myers Squibb, Princeton, New Jersey, USA;

5. Evidera, Bethesda, Maryland, USA;

6. Evidera, Seattle, Washington, USA;

7. University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, North Carolina, USA.

Abstract

INTRODUCTION: The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study. METHODS: Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo. RESULTS: A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (−4.67 vs −1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (−4.48 vs −0.04; P = 0.0079). DISCUSSION: Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference8 articles.

1. Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis;Schoepfer;Gastroenterology,2014

2. Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis;Dellon;Aliment Pharmacol Ther,2013

3. Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease;Martin;J Allergy Clin Immunol,2015

4. IL-13 involvement in eosinophilic esophagitis: Transcriptome analysis and reversibility with glucocorticoids;Blanchard;J Allergy Clin Immunol,2007

5. RPC4046, A novel anti-interleukin-13 antibody, blocks IL-13 binding to il-13 α1 and α2 receptors: A randomized, double-blind, placebo-controlled, dose-escalation first-in-human study;Tripp;Adv Ther,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Evaluation of the Adult with Eosinophilic Esophagitis;Immunology and Allergy Clinics of North America;2024-01